{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T01:38:50Z","timestamp":1763429930151,"version":"3.37.3"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"am","delay-in-days":363,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.clml.2023.11.004","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T07:17:01Z","timestamp":1701069421000},"page":"141-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen T.","family":"Chifotides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0001","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1080\/10428194.2021.1992756","article-title":"Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States","volume":"63","author":"Verstovsek","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.11.004_bib0002","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2023.11.004_bib0003","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.11.004_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106809","article-title":"Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia","volume":"115","author":"Pemmaraju","year":"2022","journal-title":"Leukemia Res"},{"issue":"9","key":"10.1016\/j.clml.2023.11.004_bib0005","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.11.004_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106905","article-title":"Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis","volume":"119","author":"Lucijanic","year":"2022","journal-title":"Leukemia Res"},{"issue":"12","key":"10.1016\/j.clml.2023.11.004_bib0007","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1002\/ajh.25270","article-title":"Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger","volume":"93","author":"Szuber","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0008","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/10428194.2022.2070914","article-title":"Excess mortality in younger patients with myeloproliferative neoplasms","volume":"64","author":"Abu-Zeinah","year":"2023","journal-title":"Leuk. Lymphoma."},{"issue":"1","key":"10.1016\/j.clml.2023.11.004_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.11.004_bib0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0011","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","article-title":"The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts","volume":"58","author":"Scherber","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2023.11.004_bib0012","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3390\/biomedicines11071925","article-title":"Identifying patients with polycythemia vera at risk of thrombosis after hydroxyurea initiation: the polycythemia vera-advanced integrated models (PV-AIM) project","volume":"11","author":"Verstovsek","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.clml.2023.11.004_bib0013","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41408-018-0151-y","article-title":"Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases","volume":"8","author":"De Stefano","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0014","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","article-title":"Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera","volume":"119","author":"Alvarez-Larr\u00e1n","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0015","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.11.004_bib0016","unstructured":"Network NCC. Myeloproliferative Neoplasms (Version 1.2023). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn_blocks.pdf. Accessed: August 11, 2023 2023."},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.clml.2023.11.004_bib0018","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/ajh.23676","article-title":"JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events","volume":"89","author":"Alvarez-Larr\u00e1n","year":"2014","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.clml.2023.11.004_bib0019","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00277-017-3040-8","article-title":"Thromboses and hemorrhages are common in MPN patients with high JAK2V617F allele burden","volume":"96","author":"Bertozzi","year":"2017","journal-title":"Ann Hematol"},{"issue":"12","key":"10.1016\/j.clml.2023.11.004_bib0020","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41408-021-00581-6","article-title":"JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis","volume":"11","author":"Guglielmelli","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2023.11.004_bib0021","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.18632\/oncotarget.986","article-title":"Jak2V617F myeloproliferative neoplasm stem cells and interferon-alpha","volume":"4","author":"Lane","year":"2013","journal-title":"Oncotarget"},{"issue":"18","key":"10.1016\/j.clml.2023.11.004_bib0023","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"121","author":"Mullally","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2023.11.004_bib0024","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3390\/cancers12071954","article-title":"Use of Interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature","volume":"12","author":"How","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.clml.2023.11.004_bib0025","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.clml.2020.05.018","article-title":"Interferon therapy in myelofibrosis: systematic review and meta-analysis","volume":"20","author":"Bewersdorf","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.clml.2023.11.004_bib0026","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/s41375-021-01183-8","article-title":"Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival","volume":"35","author":"Abu-Zeinah","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0027","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2020-141796","article-title":"Interferon in polycythemia vera (PV) yields improved myelofibrosis-free and overall survival","volume":"136","author":"Abu-Zeinah","year":"2020","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.11.004_bib0029","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.11.004_bib0030","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1182\/blood-2008-09-176818","article-title":"Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference","volume":"113","author":"Barosi","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.11.004_bib0031","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/s41375-022-01528-x","article-title":"Long-term outcomes of polycythemia vera patients treated with ropeginterferon alfa-2b","volume":"36","author":"Kiladjian","year":"2022","journal-title":"Leukemia"},{"issue":"suppl 3","key":"10.1016\/j.clml.2023.11.004_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.HS9.0000843676.80508.b5","article-title":"Ropeginterferon alfa-2b achieves patient-specific treatment goals in polycythemia vera: final results from the PROUD-PV\/CONTINUATION-PV studies","volume":"6","author":"Gisslinger","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0033","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1182\/blood-2022-156889","article-title":"Efficacy and safety of long-term Ropeginterferon alfa-2b treatment in patients with low-risk and high-risk polycythemia vera","volume":"140","author":"Kiladjian","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0034","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","article-title":"Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (low-PV study): a multicentre, randomised phase 2 trial","volume":"8","author":"Barbui","year":"2021","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evidence"},{"issue":"2","key":"10.1016\/j.clml.2023.11.004_bib0036","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jfma.2020.08.021","article-title":"Real-world experience with Ropeginterferon-alpha 2b (Besremi) in Philadelphia-negative myeloproliferative neoplasms","volume":"120","author":"Huang","year":"2021","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"10.1016\/j.clml.2023.11.004_bib0037","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/fon-2022-1141","article-title":"A phase II trial to assess the efficacy and safety of ropeginterferon \u03b1-2b in Chinese patients with polycythemia vera","volume":"19","author":"Jin","year":"2023","journal-title":"Future Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0038","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1182\/blood-2022-168687","article-title":"A single-arm, open-label, multicenter study to assess molecular response of P1101 therapy in patients with polycythemia vera and elevated hematocrit","volume":"140","author":"Lee","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.11.004_bib0039","first-page":"PB2053","article-title":"Final results from PEN-PV study, a single arm phase 3 trial assessing the ease of self-administrating ropeginterferon alfa-2b using a pre-filled pen in polycythemia vera patients","author":"Gisslinger","year":"2017","journal-title":"Eur Hematol Assoc"},{"issue":"5","key":"10.1016\/j.clml.2023.11.004_bib0040","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.11.004_bib0041","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.11.004_bib0042","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0043","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.11.004_bib0044","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1016\/j.clml.2023.11.004_bib0045","article-title":"Characteristics and clinical outcomes of patients with polycythemia vera receiving ruxolitinib after hydroxyurea: a longitudial analysis from REVEAL","volume":"7","author":"Gerds","year":"2023","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.clml.2023.11.004_bib0046","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/bloodadvances.2019001158","article-title":"Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis","volume":"4","author":"Masciulli","year":"2020","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2023.11.004_bib0047","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/cncr.34195","article-title":"Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance\/intolerance to hydroxyurea","volume":"128","author":"Alvarez-Larr\u00e1n","year":"2022","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2023.11.004_bib0048","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1200\/JCO.22.01935","article-title":"Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial","volume":"41","author":"Harrison","year":"2023","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2023.11.004_bib0049","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","article-title":"Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project","volume":"121","author":"Barosi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0050","doi-asserted-by":"crossref","first-page":"e721","DOI":"10.1097\/HS9.0000000000000721","article-title":"European LeukemiaNet response predicts disease progression but not thrombosis in polycythemia vera","volume":"6","author":"Tremblay","year":"2022","journal-title":"HemaSphere"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0051","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2014.12.008","article-title":"Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I","volume":"15","author":"Mesa","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2023.11.004_bib0052","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00277-022-05080-7","article-title":"Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group","volume":"102","author":"Koschmieder","year":"2023","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.clml.2023.11.004_bib0053","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","article-title":"Ruxolitinib and interferon-\u03b12 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study","volume":"105","author":"S\u00f8rensen","year":"2020","journal-title":"Haematologica"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0054","first-page":"6806","article-title":"Combination therapy with ruxolitinib and interferon in newly diagnosed patients with polycythemia vera","volume":"140","author":"Lindholm","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0055","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-017-3225-1","article-title":"Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies","volume":"97","author":"Kiladjian","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.clml.2023.11.004_bib0056","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2023.11.004_bib0057","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2015-10-676742","article-title":"Minihepcidin peptides as disease modifiers in mice affected by \u03b2-thalassemia and polycythemia vera","volume":"128","author":"Casu","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.11.004_bib0058","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2020-141670","article-title":"Mechanism of systemic iron regulation and hematocrit control by hepcidin peptidomimetics in pre-clinical models","volume":"136","author":"Taranath","year":"2020","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2023.11.004_bib0059","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","article-title":"Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients","volume":"40","author":"Hoffman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.clml.2023.11.004_bib0060","article-title":"Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patients","volume":"7","author":"Kuykendall","year":"2023","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0061","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2021-149205","article-title":"Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy","volume":"134","author":"Ginzburg","year":"2021","journal-title":"Blood"},{"issue":"suppl 16","key":"10.1016\/j.clml.2023.11.004_bib0062","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/JCO.2022.40.16_suppl.7003","article-title":"Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients","volume":"40","author":"Hoffman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"10.1016\/j.clml.2023.11.004_bib0063","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/S2152-2650(22)01462-8","article-title":"MPN-469 Rusfertide (PTG-300) treatment interruption reverses hematological gains and upon reinitiation, restoration of clinical benefit observed in patients with polycythemia vera","volume":"22","author":"Pemmaraju","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0064","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1182\/blood.2018893545","article-title":"Oral idasanutlin in patients with polycythemia vera","volume":"134","author":"Mascarenhas","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.11.004_bib0065","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1182\/blood-2019-123546","article-title":"A randomized, open-label, multicenter, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of KRT-232 compared with Ruxolitinib in patients with phlebotomy-dependent polycythemia vera","volume":"134","author":"Gotlib","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0066","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.leu.2405049","article-title":"The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)","volume":"22","author":"Guerini","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.11.004_bib0067","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1365-2141.2010.08266.x","article-title":"A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms","volume":"150","author":"Rambaldi","year":"2010","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2023.11.004_bib0068","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41375-020-0735-y","article-title":"Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib\/II study","volume":"34","author":"Rambaldi","year":"2020","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.11.004_bib0069","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.12332","article-title":"A phase II study of givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy","volume":"161","author":"Finazzi","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0070","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-021-00445-z","article-title":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1\/2 studies and a compassionate use program","volume":"11","author":"Rambaldi","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2023.11.004_bib0071","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: an emerging treatment for polycythemia vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opinion Invest. Drugs"},{"issue":"3","key":"10.1016\/j.clml.2023.11.004_bib0072","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.18650","article-title":"Characterization of myeloproliferative neoplasms in the paediatric and young adult population","volume":"201","author":"Harris","year":"2023","journal-title":"Br J Haematol"},{"issue":"suppl","key":"10.1016\/j.clml.2023.11.004_bib0073","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1182\/blood-2023-185108","article-title":"Impact of cytoreductive drugs upon outcomes in a contemporary cohort of adolescent and yound adults with essential thrombocythmeia and polycythemia vera","volume":"142","author":"Beauverd","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.11.004_bib0074","unstructured":"Bose P, Masarova L, Amin HM, Verstovsek S. Philadelphia chromosome-negative myeloproliferative neoplasms. In: The MD Anderson Manual of Medical Oncology. Chapter 6, 4th ed. Kantarjian HM, Wolff RA, Rieber AG. eds., McGraw Hill: China, pp. 119-162."},{"issue":"5","key":"10.1016\/j.clml.2023.11.004_bib0075","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2023.11.004_bib0076","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (BP-MPN) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Inter Rev Cell Mol Biol"},{"key":"10.1016\/j.clml.2023.11.004_bib0077","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2023021503","article-title":"Moving towards disease modification in polycythemia vera","volume":"142","author":"Bewersdorf","year":"2023","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T22:20:15Z","timestamp":1709245215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2152265023021821"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}